Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
ACADEMIA
Avigan Interim Analysis Not Intended to Determine Efficacy, Research Sponsor Says on Reports
On the heels of news reports that Fujifilm’s antiviral Avigan (favipiravir) failed to show clear efficacy against COVID-19 in interim analysis results from one of its clinical trials, the program’s sponsor issued a statement on May 20, stressing that the…
To read the full story
Related Article
- Fujifilm Inks Global Avigan Deal with Dr. Reddy’s, Global Response Aid
July 2, 2020
- Fujifilm’s Avigan COVID-19 Trial Might Continue into July
June 9, 2020
- Japan Drops May-End Goal for Avigan’s COVID-19 Approval
May 27, 2020
- Govt Won't Require Fujifilm-Sponsored Trial Data to Approve Avigan for COVID-19: Abe
May 18, 2020
- Kato Repeats May-End Goal for Avigan OK, Negative for Use in Mildly Ill Patients
May 11, 2020
ACADEMIA
- Yanagisawa Wins Lasker Award for Unlocking Orexin’s Role in Sleep
September 10, 2026
- Generic Shortage Response Evolves into Wakayama’s 1st Regional Formulary
September 3, 2026
- Japan Cancer Database Initiative Aims to Bolster Trial Environment
August 26, 2026
- NEJM Retracts Paper on Tavneos’ Pivotal Study
July 1, 2026
- Urine-Derived Stem Cells Eyed as New Drug Discovery Tool
June 10, 2026
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…